dm+d

417440006

Articles

Search Articles

New Medicines

Respreeza (EU), Zemaira (US) Prevention of acute graft versus host disease (GvHD) following/during allogeneic haematopoietic stem cell transplant - first-line

Information

Respreeza (EU), Zemaira (US)
Licence extension / variation
CSL Behring
CSL Behring

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Serine endopeptidase inhibitor. Human alpha1-proteinase inhibitor is a normal constituent of human blood. Given as a weekly infusion over 15 minutes when used to treat alpha1-proteinase inhibitor deficiency.
The burden of diagnosed graft versus host disease (GvHD) is expected to increase at an annual growth rate (AGR) of 2.18% from around 18,000 cases in 2018 to 22,500 cases in 2028 in the seven major markets (including the UK). In 2028, it is predicted there will be 2,000 incident cases in men and women, with an AGR of 3.8%. The increase is partly attributed to the rising trend in transplantation in the 7MM, combined with underlying demographic changes in the respective markets [1].
Prevention of acute graft versus host disease (GvHD) following/during allogeneic haematopoietic stem cell transplant - first-line
Intravenous infusion